This study forms part of the GENCAF pilot program conducted between January 2020 and December 2023, using a descriptive pilot implementation design. Primary implementation outcomes assessed included: feasibility (enrollment and counseling completion rates), workforce development (number of professionals trained and certified), fidelity (adherence to standardized counseling protocols), and initial efficacy (P/LP diagnostic yield). Ethical approval was obtained from the National Human Health Research Ethics Committee (N˚2021/12/1424/CE/CNERSH/SP). The program was implemented across three major oncology centers in Yaounde: the Yaounde General Hospital, Yaounde Central Hospital, and the NGO Chemotherapy Solidarity (SOCHIMIO), collectively accounting for an estimated 80% of cancer consultations in the capital region at this period.

To address the absence of specialized personnel in cancer genetics, GENCAF utilized a “train-the-trainer” model [12]. Two Cameroonian physicians completed a hybrid four-month intensive oncogenetics immersion program at the City of Hope National Medical Center in California, USA, becoming Cameroon’s first formally trained cancer genetic counselors. Following their return in 2021, they conducted onsite training workshops for 19 local health professionals across the three participating institutions, covering pedigree construction, identification of hereditary cancer red flags, and pre/post-test counseling protocols.

A South-South reinforcement mission from the University of Ibadan, Nigeria, provided advanced training in variant classification per American College of Medical Genetics and Genomics and Association for Molecular Pathology (ACMG/AMP) guidelines, management of BRCA-associated cancer syndromes, and cascade testing strategies for at-risk family members [13].

The feasibility and acceptability of genetic counseling and testing services among Cameroonian cancer patients were evaluated in a prior cross-sectional study among 160 patients, the full methods and results of which have been published separately [11]. That study demonstrated near-universal willingness to undergo counseling and testing, with cost identified as the primary barrier. Its findings provided the social and ethical foundation for the operational phase described here.

GENCAF developed Cameroon’s first clinical guidelines for hereditary cancer genetic counseling, adapted to the local context. The protocol included standardized procedures for pre-test counseling (covering cancer risk mechanisms, inheritance patterns, penetrance, and psychosocial implications), three-generation pedigree construction, informed consent in both French and English, and saliva sample collection using Color Genomics collection kits allowing room-temperature storage without cold-chain logistics.

Between May 2022 and December 2023, 94 patients were enrolled for germline multigene panel testing. Referral criteria for suspected hereditary cancer included at least one of the following: 1) breast or ovarian cancer at age ≤ 45 years; 2) triple-negative breast cancer at any age; 3) two or more first- or second-degree relatives with breast, ovarian, colorectal, gastric, or prostate cancer; 4) bilateral or multicentric breast cancer; 5) male breast cancer; or 6) personal or family history suggestive of a recognized hereditary syndrome (Lynch syndrome, Li-Fraumeni syndrome, familial adenomatous polyposis). Family history of cancer was defined as at least one first- or second-degree relative with a documented cancer diagnosis. Additional eligibility criteria included: 2) completion of pre-test genetic counseling; and 3) successful saliva-based DNA collection and valid sequencing results.

Saliva samples were shipped to Color Genomics Laboratory (Burlingame, California, USA), a College of American Pathologist-accredited, Clinical Laboratory Improvement Amendments-certified laboratory, for NGS analysis using a 29-gene hereditary cancer panel. Sequencing was performed at minimum coverage >20× for >99% of targeted regions. Variants were classified per ACMG/AMP guidelines into P, LP, VUS, likely benign, or benign. Copy-number variant (CNV) detection was performed using depth-of-coverage algorithms. Pathogenic or likely pathogenic variants in genes other than BRCA1/2 were confirmed by Sanger sequencing. Post-test counseling for P/LP and VUS carriers included result interpretation, cancer risk discussion, enhanced surveillance recommendations based on National Comprehensive Cancer Network (NCCN) guidelines [14], and cascade testing guidance.

Data were collected on standardized questionnaire forms and entered into a secure REDCap database. Descriptive statistics were used to summarize baseline characteristics and genetic findings. Pre- and post-counseling knowledge scores were compared using paired t-tests. Statistical significance was set at p < 0.05. Analyses were performed using SPSS version 23.

The GENCAF program established Cameroon’s first multidisciplinary cancer genetics team. Two physicians who completed intensive training in the United States became the country’s first formally certified cancer genetic counselors, providing clinical genetic counseling services from late 2020. These counselors subsequently trained 19 additional health professionals (12 oncology residents, 5 nurses, 2 general practitioners) across the three participating institutions.

By the end of 2023, the GENCAF team had conducted 96 genetic counseling sessions, constructed 90 detailed three-generation pedigrees, and established standardized counseling protocols. Capacity-building efforts extended to educational presentations at national oncology conferences and training sessions for medical students.

Of 112 patients who underwent pre-test genetic counseling between May 2022 and December 2023, 94 proceeded to multigene germline testing (84%). Reasons for non-testing included the fear of the results. Of the 96 counseling sessions reported, 2 involved patients who ultimately declined testing. All 94 tested patients yielded valid sequencing results (Figure 1).

Figure 1. GENCAF program implementation timeline and key milestones (2020-2023). Phases shown as horizontal bars; diamonds indicate key milestones. GENCAF: Genetic Counseling and Cancer Testing in Africa; SOP: standard operating procedure.

The feasibility and acceptability outcomes (including knowledge-score improvement from 41% to 78%, p < 0.001) were measured in a prior cross-sectional cohort of 160 patients and are not outcomes of the present testing cohort of 94 patients [11]. That study documented near-universal willingness to undergo genetic counseling (98%) and testing (96% - 97.5%), high motivation driven by desire to protect family members (81%) and understand cancer origin (84%), and cost as the predominant barrier (91%). These findings confirmed the social readiness of the Cameroonian population for hereditary cancer genetic services and provided the foundational justification for the operational testing phase.

Between May 2022 and December 2023, 94 patients underwent germline multigene panel testing. The median age was 45 years (IQR 37 - 53); 95.7% were female. Cancer types included breast (87.2%, n = 82), colorectal (5.3%, n = 5), gastric (3.2%, n = 3), ovarian (2.1%, n = 2), renal (1.1%, n = 1), and prostate (1.1%, n = 1).

Table 1. Pathogenic and likely pathogenic variants by gene amongst mutation genes and amongst the whole population (N = 94).

Figure 2. Variant classification distribution (n = 94).

Table 1 shows the pathogenic and likely pathogenic variants by gene amongst mutation genes and amongst the whole population, and the hereditary syndromes. Among the 94 tested patients, 57 (60.6%) reported a positive family history of cancer (at least one first- or second-degree relative with a documented malignancy). Early-onset disease was common, with 43 patients (45.7%) diagnosed before age 45. The primary indication for testing was breast cancer (n = 82, 87.2%), followed by colorectal (n = 5, 5.3%), gastric (n = 3, 3.2%), ovarian (n = 2, 2.1%), renal (n = 1, 1.1%), and prostate (n = 1, 1.1%) cancer. The sequencing success rate was 100%. P/LP variants were identified in 26 patients (27.7%; 25 pathogenic, 1 likely pathogenic). VUS were detected in 25 patients (26.6%). Overall, 43 patients (45.7%) carried at least one variant of any classification. Eight patients carried both a P/LP variant and a VUS in different genes. Figure 2 and Figure 3 summarize overall the variants distribution and pathogenic/likely pathogenic variants by gene.

Figure 3.Distribution of Pathogenic/Likely Pathogenic carriers per gene (26 carriers).

BRCA1 was the most frequently mutated gene (19.1% of the cohort; 17 pathogenic + 1 likely pathogenic), followed by PALB2 (2.1%), BRCA2 (2.1%), PMS2 (2.1%), MSH2 (1.1%), and ATM (1.1%). Figure 4 and Figure 5 illustrate the pedigree and the results of a 57-year-old female with risk factors of breast cancer and a positive family history who presented an ATM mutation.

Figure 4.Pedigree of a 57-year-old female with risk factors of breast cancer and a positive family history who presented an ATM mutation.

Figure 5.Genetic testing result of a 57-year-old female with risk factors of breast cancer and a positive family history who presented an ATM mutation.

Several limitations warrant consideration. First, the study was conducted at urban tertiary centers in Yaounde, potentially limiting generalizability to rural populations. Second, the sample size (N = 94) limits statistical power for comparing variant rates across cancer types. Third, the use of an international laboratory introduces delays and costs not representative of a mature national program. Fourth, the absence of local sequencing capacity limits the long-term sustainability of the program without external funding.